Development of COVID-19 Vaccine Candidates Using Attenuated Recombinant Vesicular Stomatitis Virus Vectors with M Protein Mutations.

Viruses · 2025 · PMC12390721 · PMID 40872776

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Although the p -value was between 0.05 and 0.1, which is marginally significant, this observation suggests that the M protein mutant rVSVs have a slower replication rate in vivo, leading to enhanced reactogenicity compared to rVSV-JN.1.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.